Skip to content


Open Access

Endothelial to mesenchymal transition (EndMT): an active process in Chronic Obstructive Pulmonary Disease (COPD)?

Respiratory Research201617:20

Received: 17 December 2015

Accepted: 17 February 2016

Published: 22 February 2016


Small airway fibrosis is the main contributor to physiological airway dysfunction in COPD. One potential mechanism contributing to small airway fibrosis is epithelial mesenchymal transition (EMT). When associated with angiogenesis (so called EMT-Type-3) it may well also be the link with the development of airway epithelial cancer, which is closely associated with COPD and predominantly in large airways. In a recent study published in Respiratory Research, Reimann and colleagues, showed increased expression of S100A4 in vasculature of human COPD and murine lungs. It is quite possible that the process of endothelial to mesenchymal transition (EndMT) is active in COPD lungs which we wish to comment on.


Epithelial mesenchymal transition (EMT)Small airwaysLarge airwaysCOPDLung cancerEndothelial to mesenchymal transition (EndMT)Airway remodelling


COPD is mainly caused by smoking, at least in the western countries and presents with shortness of breath that is progressively irreversible and associated with an abnormal inflammatory response of the airways in response to noxious particles and gases [1]. It is a worldwide health problem and the fourth most common cause of chronic disability and mortality, even in developed countries. Unfortunately, the research effort directed into this has been disproportionately weak compared to its clinical and scientific importance, and indeed COPD itself is the least researched of all common chronic conditions compared to its social importance. The term “chronic obstructive pulmonary disease” (COPD) now widely used, was first introduced into the literature in 1964 [2]. Later on in the 1970s and 1980s, sub-phenotypes such as emphysema, chronic bronchitis, chronic obstructive bronchitis and chronic bronchitis with emphysema were used [3]. It is a complex disease, and can have both airway and lung parenchymal components involved. Pathologically, it involves structural changes in lung parenchyma, airways, vessels [4]. Remodelling in COPD, may occur in response to smoking-induced damage to the lungs, but the details of structural changes and underlying mechanism are poorly described or understood [4]. One potential mechanism contributing to small airway fibrosis/obliteration and epithelial cancers in COPD is epithelial mesenchymal transition (EMT) [59]. Vascular remodelling has also been widely reported in COPD both in mild to severe disease but the mechanisms behind, again are poorly understood [1013]. Recent study by Reimann and colleagues published in Respiratory Research, highlighted vascular remodelling in COPD with increase in S100A4 expression (or FSP-1, fibroblast specific protein) in vasculature of human COPD and murine lungs [14]. Authors discussed the importance of vascular remodelling in pathophysiology of COPD, however there is no clear information on how S100A4 might be contributing to the vascular remodelling in COPD. It is quite possible that the process of endothelial to mesenchymal transition (EndMT) is active in COPD lungs (Fig. 1).
Figure 1
Fig. 1

Potential contribution of epithelial mesenchymal transition (EMT) and endothelial mesenchymal transition (EndMT) to pathogenies of COPD and its linkage to lung cancer through formation of pro-cancer stroma

Main text

The classically described process of EMT involves phenotypic change and migration of epithelial cells into the sub-epithelial mesenchyme in the lamina propria (LP) to function as extracellular-matrix producing fibroblasts/myofibroblasts [1519]. EMT is a vital process during embryogenesis (EMT-Type-I), but can also be induced as a result of persistent damage and tissue inflammation [2022]. There are then two subsequent outcome possibilities with active EMT: severe and even complete organ fibrosis (EMT-Type-II), development of a pre-malignant stroma when associated with angiogenesis (EMT-Type-III) [10, 13, 1522].

We recently published that EMT is an active process in both small and large airways of COPD patients [5, 8, 9]. Furthermore, the reticular basement membrane (Rbm) in large airways is hyper-vascular [10] i.e., give the appearance of active EMT-Type-III, and of course it is the large airways in COPD, where cancer formation is common (Fig. 1), especially squamous cell carcinoma [15, 21, 23]. In small airways no hyper-vascularity of the Rbm was observed [5], indicating that EMT-Type-II is active and contributing to small airway fibrosis and obliteration at this site, [5, 1619]. Recently in a randomized controlled trial, we also reported that inhaled corticosteroid fluticasone propionate given over six months suppressed EMT-related changes in large airways of COPD patients [24]. This was the first study reporting anti-EMT effects of inhaled corticosteroids in COPD.

Similar to the process of EMT is endothelial to mesenchymal transition (EndMT), in which endothelial cells lose their adhesion properties and apical-basal polarity to form highly invasive, migratory, spindle-shaped, elongated mesenchymal cells (fibroblasts/myofibroblasts) and contribute to different pathological processes in the organism in a number of ways [25]. EndMT is a critical process during embryogenesis, especially in embryonic cardiac development [26]. However, in response to persistent damage and inflammation, EndMT can lead to complete organ fibrosis [27] and cancer as well [25, 2730]. In malignancy, it is suggested that myofibroblasts or cancer associated fibroblasts (CAFs) produced during EndMT can facilitate tumour growth and cancer progression, which fits with the underlying pathology as the tumour tissue is heavily associated with increased angiogenesis so it is quite possible that vascular endothelial cells are contributing to the pool of CAFs (Fig. 1) by transforming into a mesenchymal cell type [28, 30, 31]. EndMT can also initiate the formation of pro-cancer stroma quite similar to EMT-Type-III, so it has the potential for both, to initiate cancer but at the same time helps the tumour to thrive [30].

Vascular remodelling has also been reported in COPD, main structural changes involve intimal and medial thickening, leading to reduction of lumen diameter and muscularization of arterioles [32]. The other changes involve hypo-vascular lamina propria and hyper-vascular Rbm in large airways of smokers and COPD [11, 13, 3335]. Both loss of vessels and vascular remodelling give rise to pulmonary hypertension in COPD [32, 36]. Interestingly, these vascular remodelling changes are also observed in early COPD and in normal lung function current smokers [11, 13, 14, 3234, 37]. Reimann and colleagues not only observed the expression of S100A4 in occulated arteries but also in very small vessels with a diameter of less than 50 μm [14]. Abnormal deposition of pulmonary smooth like cells has been considered as the key pathological feature of arterial remodelling [38]. These cells lead to increased production of extracellular matrix proteins, with deposition of collagen and elastin proteins contributing to narrowing of arterial lumen hence pulmonary hypertension. But the origin of these smooth muscle like cells and the underlying mechanisms involved in vascular remodelling are poorly understood [38].

This recent study by Reimann and colleagues brings some light to this puzzle [14]. The authors observed increased S100A4 expression in the vasculature of both human COPD and mouse lung. S100A4 is also known as a fibroblast specific protein – 1 (FSP-1), it is widely reported to be upregulated in fibrosis and cancer in different organs and is one of the key proteins which are upregulated during EMT [8, 39, 40]. We have previously reported that EMT is an active process in smokers and COPD with S100A4 as one of the key proteins up-regulated along with vimentin and others, and contributing to the fibroblasts and CAFs populations in COPD [5, 8, 9]. Increased S100A4 expression in pulmonary vasculature of COPD patients suggests that process of endothelium to mesenchymal transition (EndMT) is also active in COPD in addition to EMT. It is quite possible that the primary arterial smooth muscle cells staining positively for S100A4 are the transitioning endothelial cells [38], hence the process of EndMT is active in COPD contributing to pulmonary vascular remodelling [38]. EndMT might be the mechanism behind increased expression of S100A4 in COPD. Similar staining pattern for S100A4 was observed in vessels by our group as well when we analysed bronchial biopsies and surgically resected lung tissue from smokers and COPD for EMT related changes [5, 8, 9]. These are important observations and warrant further studies, as there are no studies in COPD so far looking for the evidence of active EndMT but it is quite possible that this process is active.


EMT is likely the process which is contributing to small airway fibrosis and large airway epithelial cancers. Vascular remodelling is also a key feature of COPD but the mechanisms behind are poorly understood. In line with current literature and observations from the recent study by Reimann and colleagues it is quite possible that the process of EndMT is active in lungs of COPD patients. EndMT is possibly contributing to vascular remodelling in COPD BUT at the same time is also potentially contributing to airway fibrosis and malignancy by producing fibroblasts and cancer associated fibroblasts (CAFs), this warrants further studies. If this is true, it will have huge implications for understanding the underlying pathology of COPD. We believe, that understanding EMT and EndMT might be the key to understanding what COPD is really about and its nasty clinical consequences.



Cancer associated fibroblasts


Chronic obstructive pulmonary disease


Extracellular matrix


Epithelial mesenchymal transition


Endothelial to mesenchymal transition


Lamina propria


Reticular basement membrane



Clifford Craig Medical Research Trust (S0023484).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

School of Health Sciences, University of Tasmania, Launceston, Australia
Breathe Well Centre of Research Excellence for Chronic Respiratory Disease and Lung Ageing, School of Medicine, University of Tasmania, Hobart, Australia


  1. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med. 2003;54:113–29.View ArticlePubMedGoogle Scholar
  2. Mitchell RS, Filley GF. Chronic obstructive bronchopulmonary disease. I Clinical Features. Am Rev Respir Dis. 1964;89:360–71.PubMedGoogle Scholar
  3. Larsson K. Aspects on pathophysiological mechanisms in COPD. J Intern Med. 2007;262(3):311–40.View ArticlePubMedGoogle Scholar
  4. Nowrin K, Sohal SS, Peterson G, Patel R, Walters EH. Epithelial-mesenchymal transition as a fundamental underlying pathogenic process in COPD airways: fibrosis, remodeling and cancer. Expert Rev Respir Med. 2014;8(5):547–59.Google Scholar
  5. Mahmood MQ, Sohal SS, Shukla SD, Ward C, Hardikar A, Noor WD, et al. Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2015;10:1515–24.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Sohal SS. Chronic Obstructive Pulmonary Disease (COPD) and lung cancer: Epithelial Mesenchymal Transition (EMT), the missing link? EBioMedicine. 2015;2(11):1578–9.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Sohal SS, Mahmood QM, Walters HE. Clinical significance of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD): potential target for prevention of airway fibrosis and lung cancer. Clin Transl Med. 2014;3(1):33.PubMed CentralView ArticleGoogle Scholar
  8. Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, et al. Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology. 2010;15(6):930–8.View ArticlePubMedGoogle Scholar
  9. Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, et al. Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respir Res. 2011;12(1):130.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Soltani A, Reid DW, Sohal SS, Wood-Baker R, Weston S, Muller HK, et al. Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study. Respir Res. 2010;11(1):105.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Soltani A, Muller H, Sohal S, Reid D, Weston S, Wood-Baker R, et al. Distinctive characteristics of bronchial reticular basement membrane and vessel remodelling in chronic obstructive pulmonary disease (COPD) and in asthma: they are not the same disease. Histopathology. 2012;60(6):964–70.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Soltani A, Sohal S, Reid D, Weston S, Wood-Baker R, Walters E. Vessel-associated transforming growth factor-Beta1 (TGF-beta1) is increased in the bronchial reticular basement membrane in COPD and normal smokers. PLoS One. 2012;7(6):e39736.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Soltani A, Wood-Baker R, Sohal SS, Muller HK, Reid D, Walters EH. Reticular basement membrane vessels are increased in COPD bronchial mucosa by both factor VIII and collagen IV immunostaining and are hyperpermeable. J Allergy (Cairo). 2012;2012:958383.Google Scholar
  14. Reimann S, Fink L, Wilhelm J, Hoffmann J, Bednorz M, Seimetz M, et al. Increased S100A4 expression in the vasculature of human COPD lungs and murine model of smoke-induced emphysema. Respir Res. 2015;16:127.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Sohal SS, Soltani A, Weston S, Wood-Baker R, Walters H. Intermediate filament vimentin and potential role in epithelial mesenchymal transition (EMT). In: Vimentin concepts and molecular mechanisms. 2013. p. 37–61.Google Scholar
  16. Sohal SS, Walters EH. Epithelial mesenchymal transition (EMT) in small airways of COPD patients. Thorax. 2013;68(8):783–4.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Sohal SS, Walters EH. Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD). Respir Res. 2013;14(1):120.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Sohal SS, Ward C, Danial W, Wood-Baker R, Walters EH. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2013;7(3):275–88.View ArticlePubMedGoogle Scholar
  19. Sohal SS, Ward C, Walters EH. Importance of epithelial mesenchymal transition (EMT) in COPD and asthma. Thorax. 2014;69:768. doi:10.1136/thoraxjnl-2014-205582.View ArticlePubMedGoogle Scholar
  20. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009;119(6):1417–9.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–37.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112(12):1776–84.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Sohal SS, Soltani A, Reid D, Ward C, Wills KE, Muller HK, et al. A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. Int J Chron Obstruct Pulmon Dis. 2014;9:533–42.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Lin F, Wang N, Zhang TC. The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life. 2012;64(9):717–23.View ArticlePubMedGoogle Scholar
  26. Kovacic JC, Mercader N, Torres M, Boehm M, Fuster V. Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease. Circulation. 2012;125(14):1795–808.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179(3):1074–80.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67(21):10123–8.View ArticlePubMedGoogle Scholar
  29. Rieder F, Kessler SP, West GA, Bhilocha S, de la Motte C, Sadler TM, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol. 2011;179(5):2660–73.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Gurzu S, Turdean S, Kovecsi A, Contac AO, Jung I. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update. World J Clin Cases. 2015;3(5):393–404.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008;99(9):1375–9.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Sakao S, Voelkel NF, Tatsumi K. The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations. Eur Respir Rev. 2014;23(133):350–5.View ArticlePubMedGoogle Scholar
  33. Soltani A, Sohal SS, Reid D, Weston S, Muller HK, Wood-Baker R, Walters EH. Basement membrane remodelling in COPD responds to inhaled corticosteroids. In: The Thoracic Society of Australia & New Zealand Annual Scientific Meeting. Brisbane, Australia: Respirology; 2010. Abstract (A33), 15 (Suppl 1), A11-A40.Google Scholar
  34. Soltani A, Sohal SS, Reid D, Weston S, Wood-Baker R, Walters EH. Vessel-associated transforming growth factor-beta1 (TGF-beta 1) is increased in the bronchial reticular basement membrane in COPD and normal smokers. PLoS One. 2012;7(6):1–5.View ArticleGoogle Scholar
  35. Zanini A, Chetta A, Imperatori AS, Spanevello A, Olivieri D. The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respir Res. 2010;11:132.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5):892–905.View ArticlePubMedGoogle Scholar
  37. Siafakas NM, Antoniou KM, Tzortzaki EG. Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2007;2(4):453–62.PubMed CentralPubMedGoogle Scholar
  38. Coll-Bonfill N, Musri MM, Ivo V, Barbera JA, Tura-Ceide O. Transdifferentiation of endothelial cells to smooth muscle cells play an important role in vascular remodelling. Am J Stem Cells. 2015;4(1):13–21.PubMed CentralPubMedGoogle Scholar
  39. Bjornland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, Aasen AO, et al. S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res. 1999;59(18):4702–8.PubMedGoogle Scholar
  40. Schneider M, Hansen JL, Sheikh SP. S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med. 2008;86(5):507–22. doi:10.1007/s00109-007-0301-3.View ArticlePubMedGoogle Scholar


© Sohal. 2016